| |
Metabolic
Syndrome News -
from
March 2008
|
| Epidemiology |
|
 Poststroke mortality inversely
related to
body mass index
(Posted: March 31, 2008)
| View
Television-viewing
time positively associated with a number of metabolic
risk variables
(Posted: March 25, 2008) |
View
Alanine
aminotransferase associated with an adverse atherothrombotic
and metabolic risk profile
in a British
South Asian population
(Posted: March 21, 2008) |
View
Several
components of the metabolic syndrome associated with
cardiovascular disease in elderly
Italians
(Posted: March 20, 2008) |
View
Adiponectin
associated with adverse cardiovascular outcome in
patients with manifest coronary artery
disease
(Posted: March 19, 2008) |
View
Main
lipid-related cardiovascular disease risk in Maori
and Pacific people is due to their
low HDL
and high
triglyceride levels.
(Posted: March 18, 2008) |
View
Importance
of sleep disordered breathing as a risk factor for
clinically important levels
of metabolic
dysfunction
(Posted: March 17, 2008) |
View
High
prevalence of the metabolic syndrome as an emerging
health problem in Iranian
women
(Posted: March 13, 2008) |
View
Strong
association between obesity and C-reactive protein
in African-Americans
and in
Hispanic-Americans
(Posted: March 11, 2008) |
View
Strong
genetic influences on childhood abdominal obesity
(Posted: March 10, 2008) |
View
Low-carbohydrate
diets rich in vegetable sources of fat and protein
may modestly reduce
the risk of
diabetes
(Posted: March 7, 2008)
| View
Metabolic
syndrome as an important predisposing factor for
depression
(Posted: March 3, 2008) |
View |
|
| Screening
& Diagnosis |
No
consistent glycaemic threshold for incident retinopathy
across different populations
(Posted: March 27,
2008) |
View
Circulating
adiponectin level as a strong risk marker for metabolic
syndrome, independent of measures
of adiposity,
insulin resistance and inflammatory markers
(Posted: March 5, 2008) |
View |
|
| Pathophysiological
Aspects |
Proliferative
diabetic retinopathy significantly associated with coronary
atherosclerosis in the Veterans Affairs Diabetes Trial
(VADT)
(Posted: March 26, 2008) |
View
Metabolic syndrome
strongly associated with lacunar infection in middle-aged
subjects
(Posted: March 14, 2008) |
View
The measurement of
dysfunctional HDL may play an important role in coronary
artery disease
risk
(Posted: March 6, 2008) |
View |
|
Metabolic
Syndrome Components / Risk Factors / Associated Risks |
Dyslipidaemia predicts the development of
hypertension in
middle-aged men,
independently of features related to the metabolic syndrome
(Posted: March 24, 2008) |
View
Achieving low triglyceride
levels may be an additional consideration beyond low LDL-cholesterol
levels for patients after acute coronary syndrome
(Posted: March 12, 2008) |
View |
|
| Prognosis
/ Outcomes |
(Cardiovascular
Disease)
Triglyceride/HDL-cholesterol ratio as an
imperfect surrogate for insulin resistance and its associated
coronary heart disease risk
(Posted: March 28, 2008) |
View |
|
Featured
Upcoming
Congresses
(May - August 2008)
|
| 16th
European
Congress
on
Obesity (ECO) |
Date:
|
|
May
14-17,
2008 |
Location:
|
|
Geneva,
Switzerland |
Website:
|
|
Click
here |
|
| AACE
17th
Annual
Meeting
and
Clinical
Congress |
Date:
|
|
May
14-18,
2008 |
Location:
|
|
Orlando,
Florida,
USA |
Website:
|
|
Click
here |
|
5th
World
Congress
on
Prevention
of
Diabetes
and
its
Complications |
Date:
|
|
June
1-4,
2008 |
Location:
|
|
Helsinki,
Finland |
Website:
|
|
Click
here |
|
| 3rd
International Symposium on Integrated Biomarkers
in Cardiovascular Disease |
Date:
|
|
July
9-11, 2008 |
Location:
|
|
Seattle,
WA |
Website:
|
|
Click
here |
|
| Australian
Diabetes Society / ADEA Annual Scientific Meeting |
Date:
|
|
August
28-30, 2008 |
Location:
|
|
Melbourne,
Australia |
Website:
|
|
Click
here |
|
| > View
all upcoming congresses |
|
Featured
Ongoing
Trials
|
Hypoglycaemic
Agents
Trial
-
STARR
STARR is a substudy of DREAM, with yearly carotid
ultrasound examination.
Outcome:
Change of mean maximum carotid intima-media thickness (IMT)
evalulated across 12 segments involving left and right
common carotid, bifurcation and internal carotid arteries
Expected
Total
Enrollment:
1200 subjects with impaired glucose tolerance or
impaired fasting glucose.
Comparisons:
Ramipril and/or rosiglitazone.
Study
Design:
Randomized, double-blind, placebo control, factorial assignment.
Lipid Modifying Agents
Trial - JUPITER
Crestor 20mg Versus Placebo in Prevention of CV Events
Outcome:
Rate of major cardiovascular events.
Expected Total Enrollment:
15,000 subjects with low to normal levels LDL-cholesterol
(<130 mg/dL) and elevated levels of C-reactive protein
(>2.0mg/L)
Comparisons:
Resuvastatin vs placebo.
Study Design:
Randomized, double-blind, placebo control, parallel assignment.
> View
all
landmark
studies
and
clinical
trials
|
|
Slide
Kit part 1:
The Main Threat To Human Health For The Next
Decade
Slide Kit part 2:
The Double
Jeopardy of the Metabolic Syndrome
Slide Kit part 3:
Defusing the Metabolic Time Bomb
Slide Kit part 4:
Combating
the Metabolic Syndrome: Action Plan
Slide Kit part 5:
Metabolic Syndrome and Insulin Resistance
|
Framingham
Risk Assessment Tool
Estimates 10-year risk of developing hard
CHD
> View
Tool
Procam Risk Calculator
Estimates your risk
of a heart attack (myocardial infarction) within the next
10 years based upon data of the PROCAM Study
> View
Calculator
SCORE
(European High Risk Chart)
Estimates 10 year risk of fatal
CVD in high risk regions of Europe by gender, age, systolic blood pressure,
total cholesterol and smoking status.
> View
Chart
UKPDS Risk Engine
The UKPDS Risk
Engine is a type 2 diabetes specific risk calculator based
on 53,000 patients years of data from the UK Prospective
Diabetes Study, which also provides an approximate 'margin
of error' for each estimate.
> View
Risk Engine
|
Mission of the Metabolic
Syndrome Institute |
Created in 2003, the Metabolic Syndrome Institute is an independent and not for profit association. Its members are international experts in lipid metabolism, diabetes, heart disease, endocrinology obesity, genetics, epidemiology, basic research and health economics. Being the first association totally devoted to the dissemination of knowledge about the metabolic syndrome, the Metabolic Syndrome Institute will provide an international multidisciplinary approach to a worldwide public health problem. |
| |
Contact Metabolic Syndrome Institute |
212, avenue Paul Doumer
92500 Rueil-Malmaison Cedex
FRANCE
Phone: (33) 1 41 42 20 35
Fax: (33) 1 41 42 20 01
Email:
contact@metabolic-syndrome-institute.org
Website:
http://www.metabolic- syndrome-institute.org |
|
